X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SANOFI INDIA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SANOFI INDIA ASTRAZENECA PHARMA/
SANOFI INDIA
 
P/E (TTM) x 62.8 35.7 175.6% View Chart
P/BV x 17.7 6.3 282.4% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 ASTRAZENECA PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
SANOFI INDIA
Dec-18
ASTRAZENECA PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,2786,840 18.7%   
Low Rs8834,630 19.1%   
Sales per share (Unadj.) Rs228.41,203.1 19.0%  
Earnings per share (Unadj.) Rs10.4165.3 6.3%  
Cash flow per share (Unadj.) Rs16.3209.9 7.7%  
Dividends per share (Unadj.) Rs084.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs98.8963.6 10.3%  
Shares outstanding (eoy) m25.0023.03 108.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.8 99.2%   
Avg P/E ratio x104.234.7 300.4%  
P/CF ratio (eoy) x66.427.3 243.1%  
Price / Book Value ratio x10.96.0 183.8%  
Dividend payout %050.8 0.0%   
Avg Mkt Cap Rs m27,008132,078 20.4%   
No. of employees `0001.43.3 41.1%   
Total wages/salary Rs m1,5354,068 37.7%   
Avg. sales/employee Rs Th4,210.98,393.8 50.2%   
Avg. wages/employee Rs Th1,132.21,232.4 91.9%   
Avg. net profit/employee Rs Th191.11,153.0 16.6%   
INCOME DATA
Net Sales Rs m5,71027,708 20.6%  
Other income Rs m123897 13.7%   
Total revenues Rs m5,83328,605 20.4%   
Gross profit Rs m4636,235 7.4%  
Depreciation Rs m1471,027 14.4%   
Interest Rs m07 0.0%   
Profit before tax Rs m4386,098 7.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,292 7.8%   
Profit after tax Rs m2593,806 6.8%  
Gross profit margin %8.122.5 36.0%  
Effective tax rate %40.837.6 108.7%   
Net profit margin %4.513.7 33.0%  
BALANCE SHEET DATA
Current assets Rs m3,20915,922 20.2%   
Current liabilities Rs m2,0706,235 33.2%   
Net working cap to sales %20.035.0 57.1%  
Current ratio x1.62.6 60.7%  
Inventory Days Days7264 113.7%  
Debtors Days Days3521 167.4%  
Net fixed assets Rs m7907,539 10.5%   
Share capital Rs m50230 21.7%   
"Free" reserves Rs m2,41921,962 11.0%   
Net worth Rs m2,46922,192 11.1%   
Long term debt Rs m00-   
Total assets Rs m4,60529,839 15.4%  
Interest coverage xNM872.1-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.9 133.5%   
Return on assets %5.612.8 44.0%  
Return on equity %10.517.2 61.2%  
Return on capital %17.727.5 64.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3007,587 3.9%   
Fx outflow Rs m2,0157,145 28.2%   
Net fx Rs m-1,715442 -388.1%   
CASH FLOW
From Operations Rs m883,739 2.4%  
From Investments Rs m-94-731 12.8%  
From Financial Activity Rs mNA-1,972 0.0%  
Net Cashflow Rs m-61,036 -0.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 60.4 124.2%  
Indian inst/Mut Fund % 0.3 14.4 2.1%  
FIIs % 15.7 14.6 107.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   12,856 15,184 84.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  ALEMBIC LTD  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks(The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 23, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS